Fulltext

Transferable data exclusivity vouchers are not the solution to the antimicrobial drug development crisis: a commentary on the proposed EU pharma regulation

Berner-Rodoreda A 1 , Cobelens F 2 , Vandamme AM 3 , Froeschl G 4 , Skordis J 5 , Renganathan E 6 Show all authors , t'Hoen E 7 , Raviglione M 8 , Jahn A 9 , Bärnighausen T 9

Affiliations 

  • 1 Heidelberg Institute of Global Health (HIGH), University Hospital, Heidelberg University, Heidelberg, Germany astrid.berner-rodoreda@uni-heidelberg.de
  • 2 Amsterdam Institute for Global Health & Development (AIGHD) and Department of Global Health, Amsterdam University Medical Centers, Amsterdam, The Netherlands
  • 3 Clinical and Epidemiological Virology, Institute for the Future, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
  • 4 Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
  • 5 Institute for Global Health, University College London (UCL), London, UK
  • 6 School of Medical and Life Sciences, Sunway University, Bandar Sunway, Malaysia
  • 7 Medicines Law & Policy, Amsterdam, The Netherlands
  • 8 Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milano, Italy
  • 9 Heidelberg Institute of Global Health (HIGH), University Hospital, Heidelberg University, Heidelberg, Germany
BMJ Glob Health, 2024 Feb 28;9(2).
PMID: 38423550 DOI: 10.1136/bmjgh-2023-014605

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications